Morphinsulfat Heumann (Morphine Sulfate)

Morphine sulfate works by binding to µ‑opioid receptors in the brain and spinal cord. This activation inhibits the release of neurotransmitters involved in pain signaling, reduces neuronal excitability, and alters the perception of pain, resulting in effective analgesia.

The appropriate dose of Morphinsulfat Heumann is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, renal and hepatic function, and other individual factors. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety of morphine sulfate in pregnancy and lactation is not fully established. It may cross the placenta and be excreted in breast milk, potentially causing respiratory depression in the newborn. Use only if the potential benefit justifies the risk, and always under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Morphine sulfate is considered a benchmark opioid due to its well‑characterized efficacy and safety profile. Compared with newer synthetic opioids, it has a longer history of clinical use, predictable pharmacokinetics, and a broad therapeutic window, but it may have a higher incidence of certain side effects such as constipation and sedation.

Morphinsulfat Heumann should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appearance has changed.

Morphinsulfat Heumann is formulated for oral administration. The tablet (or other oral dosage form) should be swallowed whole with water, unless otherwise directed by a healthcare professional. Dosing intervals and titration are individualized by the prescriber.

The most serious risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence or abuse. Patients should be monitored closely, especially during initiation, dose escalation, or when combined with other central nervous system depressants.

Morphinsulfat Heumann is contraindicated in patients with known hypersensitivity to morphine or other opioids, in those with significant respiratory depression, acute or severe bronchial asthma, and in patients who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for individuals with severe hepatic or renal impairment.